Department of Radiation Oncology, Weifang People's Hospital, Weifang, Shandong, China.
Graduate School of Medicine, Gunma University, Maebashi, Japan.
Ann Surg Oncol. 2024 Mar;31(3):1634-1642. doi: 10.1245/s10434-023-14723-6. Epub 2023 Dec 12.
The survival benefit of postmastectomy radiotherapy (PMRT) for patients with T3N0M0 breast cancer remains controversial. This study aimed to identify patients with a survival benefit from PMRT by developing a novel risk stratification model.
The study recruited 2062 patients with pT3N0M0 breast cancer from the Surveillance, Epidemiology, and End Results (SEER) database who underwent mastectomy between 2010 and 2019. Overall survival (OS) and breast-cancer-specific survival (BCSS) prognostic nomograms based on multivariate Cox regression were constructed to quantify the survival risk and classify patients into low- and high-risk groups. Subgroup analyses were undertaken to assess the role of PMRT according to age and risk stratification.
In the overall cohort, PMRT was beneficial in improving OS in patients with pT3N0 breast cancer (5-year OS, non-PMRT versus PMRT: 76.6% vs. 84.2%, P < 0.001), while the benefit on BCSS was not significant (P = 0.084). On the basis of the risk stratification nomogram, in the high-risk group, PMRT improved OS in young patients by 10.1%, OS in elderly patients by 12.4%, and BCSS by 10.2% (P < 0.05), but the use of PMRT in the low-risk group did not improve OS and BCSS in all patients (P > 0.05).
We presented a new method for quantifying risk using the nomogram to identify patients with high risk of pT3N0M0 breast cancer. This study found that older patients in the newly constructed high-risk group benefited from OS and BCSS benefits from PMRT, while for younger high-risk patients, there was only a benefit in terms of OS.
对于 T3N0M0 乳腺癌患者,保乳手术后放疗(PMRT)的生存获益仍存在争议。本研究旨在通过建立新的风险分层模型,确定从 PMRT 中获益的患者。
该研究从 2010 年至 2019 年期间接受乳房切除术的监测、流行病学和最终结果(SEER)数据库中招募了 2062 名 pT3N0M0 乳腺癌患者。基于多变量 Cox 回归构建了总生存(OS)和乳腺癌特异性生存(BCSS)预后列线图,以量化生存风险并将患者分为低危和高危组。进行了亚组分析,以根据年龄和风险分层评估 PMRT 的作用。
在总队列中,PMRT 改善了 pT3N0 乳腺癌患者的 OS(5 年 OS,非 PMRT 与 PMRT:76.6%与 84.2%,P < 0.001),但对 BCSS 的获益无统计学意义(P = 0.084)。基于风险分层列线图,在高危组中,PMRT 使年轻患者的 OS 提高了 10.1%,老年患者的 OS 提高了 12.4%,BCSS 提高了 10.2%(P < 0.05),但在低危组中使用 PMRT 并未提高所有患者的 OS 和 BCSS(P > 0.05)。
我们提出了一种使用列线图量化风险的新方法,以确定患有高风险 pT3N0M0 乳腺癌的患者。本研究发现,在新构建的高危组中,年龄较大的患者从 OS 和 BCSS 中受益于 PMRT,而对于年轻的高危患者,仅在 OS 方面受益。